Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics develops RNA medicines intended to restore protein expression, using its TANGO approach and antisense oligonucleotides for diseases caused by insufficient gene output. Its lead investigational medicine, zorevunersen, is in development for Dravet syndrome, with earlier work directed at rare genetic neurodevelopmental and other haploinsufficiency diseases.
Company news commonly covers zorevunersen clinical data, EMPEROR study updates, financial results, capital resources, collaboration activity, board and governance changes, equity inducement grants under Nasdaq rules, and healthcare conference presentations.
Stoke Therapeutics (Nasdaq: STOK) has priced an underwritten public offering of 2,500,000 shares at $39.00 each, expecting to raise $97.5 million. The offering will close around November 24, 2020, subject to customary conditions. Stoke has provided underwriters a 30-day option to purchase an additional 375,000 shares. Proceeds will support research, clinical development of STK-001 for Autosomal Dominant Optic Atrophy, and general corporate needs. This offering follows a registration statement with the SEC.
Stoke Therapeutics (Nasdaq: STOK) has announced a proposed underwritten public offering of up to 2,500,000 shares of common stock, with a 30-day option for underwriters to purchase an additional 375,000 shares. Proceeds from the offering will fund research and clinical development for its product candidates, including the late-stage STK-001 and new treatments for Autosomal Dominant Optic Atrophy. The offering is subject to market conditions and there are no guarantees regarding completion or terms.
Stoke Therapeutics (Nasdaq: STOK) reported Q3 2020 results, showing a net loss of $13.7 million ($0.41/share) compared to $8.6 million ($0.26/share) in Q3 2019. R&D expenses increased to $8.1 million from $6.5 million, while G&A expenses rose to $5.6 million from $3.3 million. The company continues to advance its MONARCH study for STK-001 in Dravet syndrome, with preliminary data expected in 2021. Stoke also announced the nomination of OPA1 as a preclinical target with potential to treat autosomal dominant optic atrophy, a condition currently lacking effective treatments.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on treating genetic diseases, announced that CEO Edward M. Kaye will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 3:20 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for 30 days after the event. Stoke aims to develop solutions for genetic diseases through precise protein expression upregulation, targeting conditions caused by mutated genes. For more details, visit Stoke Therapeutics.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a clinical-stage biotechnology firm, announced that CEO Edward M. Kaye, M.D., will participate in a fireside chat during the 29th Annual Credit Suisse Virtual Healthcare Conference on November 9, 2020, at 10:15 a.m. ET. This session aims to highlight the company's innovative approach to treating genetic diseases by precisely upregulating protein expression. Investors can access a live audio webcast of the chat on Stoke’s website, which will also feature a replay for 30 days.
Stoke Therapeutics (Nasdaq: STOK) is advancing its Phase 1/2a MONARCH study for STK-001, targeting Dravet syndrome, after receiving FDA approval to add higher dose levels for evaluation. The study will now assess doses of 10 mg, 20 mg, and 30 mg, with studies above 30 mg on hold. No adverse effects were noted in preclinical repeat-dose tests. The company aims to submit a protocol amendment for a multiple ascending dose segment. STK-001, an investigational drug, aims to adjust NaV1.1 protein levels, potentially modifying the disease's course.